Article

Journal of Neurology

, Volume 250, Issue 1, pp i31-i34

The relevance of preclinical studies for the treatment of Parkinson's disease

  • M. GerlachAffiliated withUniversitätsklinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Klinische Neurochemie
  • , P. FoleyAffiliated withUniversitätsklinik für Psychiatrie und Psychotherapie, Klinische Neurochemie
  • , P. RiedererAffiliated withUniversitätsklinik für Psychiatrie und Psychotherapie, Klinische Neurochemie

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract.

An essential element of pharmaceutical development, defined as the period between the discovery of a new agent and its market release, is provided by the “preclinical studies”. They consist of the in vitro and in vivo studies performed before examination of the agent in human subjects. Regulatory authorities prescribe specific requirements regarding the nature and number of preclinical studies. In the present paper, we discuss the relevance of these studies for the treatment of Parkinson's disease (PD) on the basis of three examples: the L-DOPA (L-3,4-dihydroxyphenylalanine, levodopa) story; the development of selegiline as a palliative and neuroprotective drug; and the safety concerns regarding tolcapone, an inhibitor of central and peripheral catechol-O-methyltransferase (COMT).

Key words Parkinson therapy L-DOPA therapy neuroprotection catechol-O-methyltransferase (COMT) inhibitors tolcapone selegiline